Print this page    •   Back to Web version of article

Medical News
FDA Grants Full Approval to J&J's HIV Drug

December 8, 2009

Johnson & Johnson's Tibotec division has announced the Food and Drug Administration has granted full approval to its HIV drug Intelence. The twice-daily tablet, a non-nucleoside reverse transcriptase inhibitor that works by blocking an enzyme HIV needs to multiply, is already approved for use in 50 countries. Under its accelerated approval program, FDA in January 2008 gave its permission for the drug to be marketed in the United States. However, full approval was conditional upon follow-up data about the drug's effectiveness. These data showed that 60 percent of patients on Intelence for 48 weeks had attained undetectable HIV viral loads, compared to 38 percent of control patients. Intelence is intended for HIV patients who have stopped responding to other treatments.

Back to other news for December 2009

Excerpted from:
Associated Press
11.25.2009




This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art54774.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.